PVX4 vaccine for HPV16-related cervical dysplasia
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 60 years old.
- You have been diagnosed with moderate or severe cervical dysplasia (CIN2 or CIN3) that is confirmed by a doctor.
- You test positive for HPV type 16 (a specific high-risk strain of HPV).
- You are HIV negative.
- You are willing to use birth control for 6 months after the study (if you could become pregnant).
- You have not had a cone biopsy, LEEP, or hysterectomy for cervical lesions before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests a new immunotherapy vaccine called PVX7 for women with advanced cervical cancer that is caused by HPV. It aims to see if the vaccine can help prevent the cancer from coming back after standard treatment.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2/3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.